AZD7762 is also a CHK1 inhibitor which can induce p53-deficeint, partially activate caspase 2 and downregulate E2F1 in combination with Pt, enhance the anti-tumor activity of Pt in SCLC, and overcome Pt resistance [142]. This evidence concerns the gene TP53 and neoplasm.